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Dopaminergic drugs frequently produce paradoxical effects depending on baseline
performance levels, genotype, or personality traits. The present study for the first
time aimed to specify the mechanisms underlying such opposite effects using the
following recently reported scenario as an example: depending on the personality trait
agentic extraversion (agentic facet, aE; i.e., assertiveness, dominance, ambition, positive
emotionality) the selective dopamine D2 receptor antagonist sulpiride (200mg) had
opposite effects on resting posterior vs. anterior theta activity in the electroencephalogram
(EEG). In order to better describe these opposite pharmaco-EEG effects and to generate
hypotheses regarding the underlying mechanisms, we measured the EEG intermittently
over 5 h in 80 healthy male volunteers extremely high or low in aE who had received either
placebo or one of three doses of sulpiride (50, 200, or 400mg). The findings suggest a
model postulating stronger pre- vs. postsynaptic subreceptor effects in high aE individuals
compared to low aE individuals. Future studies may now systematically apply the model to
other examples of paradoxical dopaminergic drug effects and examine the molecular basis
of individual differences in pre- vs. postsynaptic dopamine D2 subreceptor sensitivities
and densities.
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INTRODUCTION
The effects of psychopharmacological manipulations of
dopamine often show striking variability across individuals
with the same drug (e.g., a dopamine agonist, a dopamine
antagonist, caffeine) either increasing or decreasing measures
of brain activity, cardiovascular activity, mood reaction and
task performance depending on baseline values (Takeshita and
Ogura, 1994; Bitsios et al., 2005), baseline performance (Mehta
et al., 2004; Finke et al., 2010), dopamine synthesis capacity
(Cools et al., 2009), working memory span (Kimberg et al.,
1997, 2001; Mattay et al., 2000; Mehta et al., 2000; Gibbs and
D’Esposito, 2005, 2006; Frank and O’Reilly, 2006; Wallace et al.,
2011), dopaminergic genotypes (Mattay et al., 2003; Kirsch
et al., 2006; Apud et al., 2007; Cohen et al., 2007; Roussos et al.,
2009; Mueller et al., 2011; van Holstein et al., 2011; Rokem
et al., 2012) and personality traits like psychoticism (Corr and
Kumari, 2000), sensation seeking (Netter and Rammsayer, 1991;
Hutchison et al., 1999), impulsivity (Corr and Kumari, 1997;
Cools et al., 2007; Clatworthy et al., 2009; Zack and Poulos,
2009), and extraversion (Revelle et al., 1976; Rammsayer et al.,
1993; Corr and Kumari, 1997; Rammsayer, 1998; Wacker et al.,
2006; Wacker and Stemmler, 2006; White et al., 2006; Chavanon
et al., 2007; Smillie and Gokcen, 2010). Understanding the
precise mechanisms underlying such paradoxical effects would
offer important insights into the dopaminergic foundations of
various domains of personality. In the present study, we aim to
explore these mechanisms using the strong moderating effect of
extraversion on the consequences of the dopamine D2 receptor
antagonist sulpiride on resting electroencephalogram (EEG)
theta topography observed by Wacker et al. (2006) as an example.
The study by Wacker et al. (2006) aimed to test Depue
and Collins’ (1999) suggestion that individual differences in a
dopamine-based incentive motivational system, the Behavioral
Facilitation System (BFS), underlies the personality trait of
extraversion—more specifically its agentic facet (aE) encom-
passing drive, achievement striving, assertiveness as well as
positive affective motivational states (elation, desire—wanting,
energy) and vigorous and persistent goal-directed behavior
in a wide range of achievement-related and social contexts 1.
Neurobiologically the BFS, which closely resembles Gray’s (1994)
1Although impulsivity is often viewed as a potential trait manifestation of
dopamine (for recent research supporting this view see e.g., Dalley et al., 2007;
Buckholtz et al., 2010) and as the trait resulting from individual differences
in reward and incentive salience processing, empirically it seems to be more
strongly related to serotonin (see reviews and data by Carver, 2005; Crockett
et al., 2009; Robbins and Crockett, 2010). Moreover, it should be noted that
the most common measures of impulsivity are heterogenous encompassing
items assessing agentic extraversion and constraint (lower order traits like risk
taking, novelty seeking, boldness, adventuresomeness, boredom susceptibil-
ity) or assessingmotor and cognitive impulsivity. For this reason, measures of
impulsivity are neither consistently highly interrelated, nor consistent in their
correlation with extraversion (Depue and Collins, 1999). Thus, the Depue
model only predicts significant empirical relations between impulsivity and
dopamine for those measures of impulsivity more closely related to aE.
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Behavioral Approach System, is tied to the mesocorticolimbic
dopamine system (MDS; Depue and Collins, 1999) which plays
an important role in reward processing (Knutson and Cooper,
2005; Berridge, 2007) and projects from the dopaminergic cells
of the ventral tegmental area (VTA) to limbic and cortical
areas, such as the nucleus accumbens, cingulate cortex, pre-
frontal and orbitofrontal cortex (Depue and Collins, 1999; Wise,
2004; Bjorklund and Dunnett, 2007). Individual differences in
functional properties of the MDS are thought to create respec-
tive differences in the BFS and hence in incentive motivation,
approach/goal-directed behavior and aE (Depue and Collins,
1999). Consequently, aE should be associated with individual
differences in brain dopamine.
Broadly supporting the aE-dopamine hypothesis, neuroimag-
ing studies have reported associations between extraversion and
activation at rest or in response to positive or rewarding stimuli
within regions such as ventral striatum (i.e., caudate, puta-
men, nucleus accumbens), amygdala, medial orbitofrontal cor-
tex (OFC), and anterior cingulate cortex (ACC; Canli et al.,
2002; Kumari et al., 2004; Mobbs et al., 2005; Deckersbach
et al., 2006) that Depue and Collins (1999) identified as par-
ticularly important in the dopaminergic circuitry of reward and
approach behavior. In addition, psychopharmacological studies
linked extraversion to individual differences in the hormonal
response to a challenge with a selective dopamine receptor agonist
(Depue et al., 1994; Depue, 1995) and molecular genetic stud-
ies have repeatedly found associations between extraversion and
variants of dopaminergic genes (e.g., Reuter and Hennig, 2005;
Reuter et al., 2006; Smillie et al., 2010).
Rather than focusing exclusively on genetic contributions and
instead of using either expensive neuroimaging technology or
invasive measurements of blood hormone levels Wacker et al.
(2006) opted for an easily obtainable non-invasive EEG index,
for which they expected both an association with aE and sensi-
tivity to MDS activity: posterior vs. anterior EEG theta activity.
In the meantime, the correlation between aE and this mea-
sure was replicated in several studies (Knyazev, 2009, 2010;
Wacker and Gatt, 2010; Köhler et al., 2011). Recent studies
using the low-resolution electromagnetic tomography algorithm
(LORETA) suggest that major sources of posterior vs. ante-
rior EEG theta index are likely located in the ACC (Knyazev,
2010; Chavanon et al., 2011) and the OFC (Knyazev et al.,
2012). Also, initial molecular genetic studies have related poste-
rior vs. anterior EEG theta activity to the COMT polymorphism
(Val/Val carriers displayed increased posterior vs. anterior EEG
theta activity and higher E scores; Wacker and Gatt, 2010)
and the dopamine D2 receptor (DRD2) polymorphisms SNP19
rs1076560 and -141C Ins/Del (Köhler et al., 2011). For this
index of resting posterior vs. anterior, EEG theta activity Wacker
et al. (2006) observed that instead of the usual positive cor-
relation with aE a significant negative correlation was present
after administration of sulpiride (200mg). Thus, sulpiride had
completely opposite effects in individuals high vs. low in
extraversion.
Besides aE, neuropharmacological studies have revealed an
inverted U-shaped relation between working memory function-
ing and dopaminergic activity (see Arnsten, 1998, for a review).
Given that both working memory and extraversion are currently
thought to at least partly rely on brain dopamine, it seems reason-
able to assume that dopamine connects the two in a systematic
way. This suggestion is also corroborated by the fact that the
MDS, vital to the concept of aE, is also the main dopamin-
ergic projection to the frontal cortex and thus central to the
inverted U-shaped relation between working memory and frontal
dopamine. Recent studies revealed that extraversion predicts both
working memory performance (Lieberman and Rosenthal, 2001;
Chavanon et al., 2007) and working memory-related prefrontal
brain activity (Gray and Braver, 2002; Kumari et al., 2004; Gray
et al., 2005). Intriguingly, Wacker et al. (2006) reported that
the disordinal effects on EEG theta topography were paralleled
by paradoxical effects on 2- and 3-back working memory per-
formance: whereas under placebo high aE showed shorter reac-
tion times than low aE, which matched prior observations by
Lieberman and Rosenthal (2001), sulpiride reversed these reac-
tion time differences by speeding up low aE and slowing down
high aE.
Such opposing or paradoxical effects of dopaminergic drugs
have commonly been accounted for by the inverted U-shape prin-
ciple (often post-hoc): Two groups (e.g., high vs. low aE) differ
in their baseline levels of dopamine and hence occupy differ-
ent initial locations on an inverted U-shaped function linking
dopamine levels and the dependent variable. Administration of a
dopaminergic drug (e.g., a D2 agonist) shifts the groups to differ-
ent arms of the inverted U-shaped function, producing opposite
drug effects for the two groups (Figure 1). However, more direct
tests of the inverted U-shaped model that use varying drug doses
are extremely rare. At the present time there are no empirical
data available that elucidate the mechanisms on which such an
inverted U-shaped curve between dopamine and posterior vs.
anterior theta is based in the context of aE. Without specifying
which distinct processes or mechanisms contribute to an inverted
U-shaped relationship, it is just a function of representation.
However, plausible alternative explanatory models for para-
doxical effects can also be derived from the pharmacodynamic
profiles of the dopaminergic drugs administered. For exam-
ple, in the lower dosage range sulpiride enhances dopaminer-
gic transmission and dopamine synthesis (Tagliamonte et al.,
1975) as well as dopamine release by its antagonistic binding
to the presynaptic D2/D3-autoreceptors (see review by Rankin
et al., 2009), which explains its antidepressant impact, whereas
at high doses postsynaptic blockade and reduced dopamine sig-
naling predominate (Westerink and Devries, 1989; Serra et al.,
1990; Kuroki et al., 1999). Hence, those two processes might
contribute to the paradoxical effects observed by Wacker et al.
(2006). A dose of 200mg sulpiride—as used in the study by
Wacker et al. (2006)—likely produces both pre- and postsy-
naptic effects, although presynaptic effects are thought to pre-
vail (Mueller et al., 2011). Paradoxical dopaminergic effects
in different individuals might arise from systematic differences
in the time courses of pre- and postsynaptic drug effects.
For example, due to different baseline levels of dopamine the
responses to sulpiride might be shifted in time in high vs.
low aE causing differing effects at a specific point of time
(Figure 2A).
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FIGURE 1 | The relationship between dopamine level and “resting
posterior vs. anterior theta activity” follows an inverted U-shaped
function. High and low aE (aE+, aE−, respectively) differ in their initial
position on this function. After an identical increase (arrows) of the dopamine
level by either a dopaminergic agonist (e.g., bromocriptine) or a
predominantly presynaptic dopaminergic antagonist (e.g., sulpiride) aE+ and
aE− are shifted to positions (∗) that mark opposing changes (disordinal
interaction, see Substance × aE plot on the right side): aE− are shifted to
medium and aE+ to high dopamine levels, resulting in more or less posterior
vs. anterior theta activity, respectively. Such inverse U-shaped functions can
be seen as the result of two underlying processes, but without such a
specification it is merely a function of representation.
Finally, because sulpiride shows high affinity to D2 and D3
subreceptors (Strange, 2001), which are both highly expressed
in midbrain structures and function at least partly as presy-
naptic autoreceptors (Rankin et al., 2009), and a lower affin-
ity to D4 receptors, which are mostly expressed in prefrontal
cortex, hippocampus, amygdala, and pituitary (Oak et al.,
2000), sulpiride’s pharmacological profile slightly expands with
increasing doses as D4 receptors are additionally simulated 2.
Individual differences in any of these receptor densities or sen-
sitivities might lead to paradoxical effects (Figure 2B), if they
affect the balance of presynaptic (i.e., effects on DRD2 and
DRD3 presynaptic autoreceptor subtypes) vs. postsynaptic (i.e.,
effects on DRD2, DRD3, and DRD4 postsynaptic receptor sub-
types) drug effects, resulting in distinct patterns of response
dominance.
Aiming to compare the models’ (Figure 2) power to explain
aE-driven paradoxical effects of sulpiride on posterior vs. ante-
rior theta activity and 2-back working memory performance we
measured the EEG intermittently over 5 h in individuals either
extremely high or low in aE who had received either placebo or
one of three doses of sulpiride (50, 200, 400mg). We expected
that responses of individuals high and low in aE would follow
an inverted U-shaped function and/or that individuals high and
low in aE differ systematically in the time course or dominance of
sulpiride’s pre- and postsynaptic effects.
2In the past 20 years numerous studies aligned the dopamine receptor D4
gene and its polymorphisms to personality, althought there is only limited
empirical evidence to assume a DRD4—aE or approach-related personality
trait relation (for a recent meta-analysis see Munafo et al., 2008).
MATERIALS AND METHODS
PARTICIPANTS
To select participants either extremely high or low in aE, we
recruited a pool of N = 422 male, university or high school
student volunteers, to fill in a German short scale of Tellegen’s
Multidimensional Personality Questionnaire designed tomeasure
aE (see Wacker et al., 2006). In order to obtain greater homo-
geneity within aE groups the extreme group selection was based
on the primary scales: participants scoring above the median in
each of the three primary scales constituted the high aE extreme
group, whereas participants with scores below or equal to the
median in all three primary scales constituted the low aE extreme
group. By virtue of this selection procedure the participants of
the present study scored either above the top tercile (high aE)
or below the bottom tercile (low aE) of the distribution of total
aE scores. Preselected participants were further screened for their
handedness (inclusion criteria: right-handed) and participants’
health status was checked via interview: self-reports of chronic or
acute diseases especially cardiovascular or gastrointestinal ailment
or functional abnormalities of the liver or the kidney led to rejec-
tion from participation, as did habitual smoking of more than ten
cigarettes per day, regular use of other drugs, and treatment with
prescription drugs in the last 3 months. Furthermore, lifetime
absence of psychiatric disorders was ascertained by a brief clinical
interview based on DSM-IV criteria. N = 88 healthy male partic-
ipants met the inclusion criteria and finally agreed to participate
in the study. The study was approved by the Ethics Committee
of the German Society for Psychology (Deutsche Gesellschaft fuer
Psychologie) and performed in accordance with the Declaration
of Helsinki. All volunteers gave written informed consent and
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FIGURE 2 | Alternative models that might explain paradoxical sulpiride
effects in aE based on the assumption of two time and dose-related
processes (pre- and postsynaptic action). Note that both models also
assume that (1) high and low aE differ in their baseline levels of dopaminergic
activity (i.e., pre- and postsynaptic receptor activity) and hence in their
posterior vs. anterior theta activity scores and (2) posterior vs. anterior theta
linearly tracks pre- vs. postsynaptic receptor activity. Panel (A) Due to
different receptor sensitivities high and low aE (aE+, aE−, respectively) show
time-shifted pharmacological actions: For example, at 2.5 h (area marked in
light blue), the presynaptic action is still evident in aE−, but in aE+, the
postsynaptic action already occurs. This results in a paradoxical effect
(disordinal interaction, see resulting Substance × aE plot on the right side),
since, compared to baseline, aE+ displays a shift toward anterior theta
activity at 2.5 h (due to postsynaptic action), whereas aE− exhibits a shift
toward posterior theta (due to presynaptic action). Panel (B) Differential
receptor sensitivities could also produce stronger presynaptic than
postsynaptic effects in aE− resulting in a net presynaptic effect and a shift
toward posterior theta, whereas stronger sensitivity to postsynaptic action in
aE+ results in a net postsynaptic effect and a shift toward anterior theta
(marked light blue area), thus compared to baseline one observes a
paradoxical effect (disordinal interaction, see resulting Substance × aE plot
on the right side) at 2.5 h.
were paid for participation (80C, approximately $120). Eight
participants were excluded from statistical analysis, because they
had less than 30 epochs of artifact-free EEG data due to excessive
artifacts (eye and muscle movements; n = 5) or due to technical
malfunction (n = 3) in more than two data recordings. Data are
reported from 40 high-aE subjects (mean age= 22.70, SD = 2.53;
range 19–30) and 40 low-aE subjects (mean age = 23.93, SD =
3.06; range 20–31). The participants of each aE extreme group
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were randomly assigned to either the placebo or one of the three
D2 antagonist groups. A full description of the sample is given in
Table 1.
EXPERIMENTAL DESIGN
The experimental design was a placebo-controlled, double-blind
design defined by the between-subjects factors aE (high, low)
and substance (placebo, D2 antagonist sulpiride dosages 50, 200,
400mg) and the within-subjects factor time since substance (0.5,
1.5, 2.5, 3.5, and 4.5 h after substance intake).
All substances were delivered in capsules, which had the same
appearance and were matched for weight to assure that the
experimenter and the participant were blind to the pharmaco-
logical treatment. Sulpiride is a substituted benzamide deriva-
tive, shows high affinity within the nanomolar range to D2
and D3 receptors and a weaker affinity within the micromolar
range to D4 receptors (Strange, 2001), and acts predominantly
on the MDS (Mauri et al., 1996). Sulpiride appears to lack
effects on norepinephrine, acetylcholine, serotonin, histamine, or
gamma-aminobutyric acid receptors; it is rather slowly absorbed
from the gastrointestinal tract, with peak serum levels occur-
ring within 1–6 h after oral ingestion and elimination half-life
is in the range of 3–10 h (Mauri et al., 1996). A major advan-
tage of sulpiride is that adverse side effects are very rare (e.g.,
McClelland et al., 1990; Meyer-Lindenberg et al., 1997; Wacker
et al., 2006). Regarding sulpiride’s efficacy, the current literature
suggests that low doses (50–150mg) affect presynaptic autorecep-
tors producing its antidepressant efficacy, whereas higher doses
(>800mg) induce antipsychotic, postsynaptic D2 receptor effects
(Serra et al., 1990). Based on this clinical profile it is assumed that
50 and 200mg sulpiride could induce both pre- and postsynaptic
D2 receptor effects but presynaptic effects predominate (see sup-
portive data in Mueller et al., 2011). Based on the data of Mehta
et al. (2008), 400mg seems to induce stronger striatal occupancy
compared to 200mg sulpiride. In the same vein, a decreased stri-
atal activation to reward seen with 400mg sulpiride is in keeping
with the hypothesis that inhibition of dopamine transmission
(via postsynaptic effect) predominates 400mg sulpiride (McCabe
et al., 2011). In addition, the maximal prolactin response to 50
and 200mg are time shifted (Sugnaux et al., 1983): the response
to 50mg sulpiride occurred 1 h later compared to 200mg. Thus,
the postsynaptic effects dominate later in time for low compared
to high doses and consequently, presynaptic effects had to peak
earlier in time for high compared to low doses.
TWO-BACK WORKING MEMORY TASKS
In the present study, we employed the same 2-back paradigm as
in Wacker et al. (2006). Participants are presented with a series of
stimuli and asked to judge for each item as quickly and accurately
as possible whether itmatches the stimulus that preceded it by two
places in the sequence (2-back task). Participants responded to
each letter with their dominant right hand. For each of the five 2-
back tasks a pseudorandomized sequence (30% target trials; 70%
non-target trials) of 48 practice and 168 evaluated trials was gen-
erated. Of the non-target trials, 15% were lure trials, which are
1-back and 3-back repeats included as foils.
As stimuli we used single white letters (Times New Roman,
60 pt) each appearing in the center of a 15′′-TFT display for
Table 1 | Sample characteristics and descriptive statistics.
Placebo 50 200 400 Significant effects
high aE low aE high aE low aE high aE low aE high aE low aE
Age 22.2 (0.8) 23.0 (0.7) 23.0 (1.0) 24.1 (1.0) 23.2 (0.9) 24.7 (0.8) 22.4 (0.6) 23.9 (1.3)
Weight 76.6 (2.3) 71.4 (2.3) 79.1 (4.2) 80.4 (4.4) 76.0 (3.0) 83.3 (5.2) 78.9 (3.4) 80.3 (3.6)
MAE 29.6 (2.1) −7.4 (4.5) 27.6 (1.6) −11.6 (3.4) 27.6 (2.6) −6.7 (3.2) 27.3 (2.1) −8.4 (4.4) aE: 266***
MPQ NE 10.3 (2.8) 17.8 (2.2) 12.3 (2.7) 18.9 (3.7) 11.5 (2.5) 17.6 (2.7) 8.2 (1.4) 18.1 (2.5) aE: 16.61***
EPQ-R E 19.8 (0.9) 10.8 (1.7) 20.7 (0.6) 11.7 (1.3) 19.4 (1.0) 12.1 (1.6) 19.2 (1.1) 12.1 (1.9) aE: 75.63***
EPQ-R N 3.3 (0.7) 10.3 (2.0) 4.9 (1.4) 9.9 (1.9) 6.0 (1.0) 7.9 (1.2) 3.8 (1.0) 9.6 (1.8) aE: 22.82***
EPQ-R P 8.0 (2.0) 10.5 (1.1) 8.7 (1.1) 11.9 (1.7) 6.7 (1.0) 8.9 (1.2) 8.6 (1.5) 7.7 (1.4)
ZKPQ Act 8.7 (0.4) 6.9 (1.1) 10.8 (0.8) 6.0 (0.8) 11.4 (0.9) 7.2 (0.8) 10.5 (1.2) 5.1 (1.2) aE: 37.85***
ZKPQ AH 6.1 (0.9) 5.6 (0.7) 5.9 (1.3) 5.5 (0.8) 6.8 (1.0) 6.6 (0.9) 4.1 (0.7) 5.7 (0.9)
ZKPQ ImpSS 8.6 (1.4) 8.4 (1.7) 10.6 (0.9) 9.7 (1.5) 11.4 (1.0) 8.0 (1.2) 9.3 (1.5) 6.8 (0.8)
ZKPQ NA 2.2 (0.9) 6.6 (1.6) 2.4 (0.9) 4.9 (1.4) 1.9 (0.6) 3.9 (0.8) 2.1 (0.6) 5.3 (1.3) aE: 15.91***
ZKPQ Soc 11.2 (1.0) 6.0 (1.1) 10.0 (1.0) 7 (1.5) 11.0 (1.1) 6.3 (0.9) 10.4 (0.9) 8.0 (1.3) aE: 22.65***
WMC 41.3 (4.1) 38.3 (5.1) 40.3 (6.1) 35 (6.0) 33.1 (5.1) 36.3 (5.6) 35.8 (4.5) 31.4 (7.0)
CFT 26.3 (1.6) 28.3 (0.9) 31.6 (1.1) 27.3 (1.1) 26.3 (2.0) 28.5 (1.4) 29.0 (1.5) 25.9 (1.1) aE × S: 3.06*
E-P,E-200 < E50
I-400, I-50 < E50
Notes: Values given as means (standard errors). aE, Main effect agentic Extraversion, F(1, 72); aE × S: interaction of Trait aE and Substance, F(3, 72); EPQ-R,
Eysenck Personality Questionnaire Revised (E, Extraversion; P, Psychoticism; N, Neuroticism); MAE, Marburg Agentic Extraversion Scale; MPQ NE, Multidimensional
Personality Questionnaire–Negative Emotionality Scale; ZKPQ, Zuckerman–Kuhlman Personality Questionnaire (Act, activity; AH, aggression-hostility; ImpSS, impul-
sive sensation seeking; NA, neuroticism-anxiety; Soc, sociability); WMC, working memory capacity as measured by the automated span task; CFT, general fluid
intelligence as measured by the short version of the Culture Fair Test (Scale 3). *p ≤ 0.05, ***p ≤ 0.001, two-tailed.
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500ms followed by a blank, black screen for another 1650ms.
Participants were expected to respond during this 2150ms inter-
val. The end of each trial was marked by a 350-ms auditory
feedback, notifying whether the preceding reaction was correct
and fast enough (“correct,” “incorrect,” “too slow”). “Too slow”
referred to a correct reaction that was slower than a latency
criterion, which was defined as the 90th percentile of the indi-
vidual reaction time distribution for correct reactions during the
practice trials of each 2-back task. For the computation of the
individual percentiles, reaction times longer than three standard
deviations above the individual mean were excluded. A new trial
started right after the trial feedback (ITI = 0ms; ISI = 2500ms).
For each of the five 2-back task presentations, the following per-
formance measures were calculated: (a) the mean reaction time
for correct reactions to targets, (b) the percentage of correct reac-
tions to targets, and (c) the variability of reaction times for all
correct reactions. For statistical analysis the reaction times and
variability were square root transformed to normalize distribu-
tions. In order to control for unspecific attentional substance
effects, we also introduced a 0-back task. The set-up was iden-
tical to the 2-back task, but participants were asked to indicate
whether the present letter was a “q” or not. For lure trials we
used 1-back and 2-back repeats as foils. It should be noted that
Wacker et al. (2006) did not report significant effects for the
0-back task.
INTELLIGENCE TEST, WORKING MEMORY CAPACITY, AND
PERSONALITY QUESTIONNAIRES
The participants completed the short version of Cattell’s Culture
Fair Test Scale 3 (CFT; Cattell and Weiß, 1971) in order to
control for fluid intelligence as a possible confound and the
automated version of the operation span task (Unsworth et al.,
2005) in order to control for working memory capacity, which
has already been shown to produce paradoxical effects with
respect to the D2-receptor agonist bromocriptine (Kimberg et al.,
1997). In addition, participants completed the German versions
of the Zuckerman-Kuhlman Personality Questionnaire (ZKPQ;
Zuckerman, 2002), the Eysenck Personality Questionnaire-
Revised (EPQ-R; Ruch, 1999), and the MPQ-Negative
Emotionality Scale (Tellegen and Waller, 2008). EPQ-R
measures Eysenck’s personality traits of E, Neuroticism, and
Psychoticism. The ZKPQ measures Zuckerman’s “Alternative
Big Five,” Aggression-Hostility, Neuroticism-Anxiety, Sociability,
Activity, and Impulsive Sensation Seeking.
SETTING AND APPARATUS
The experiment was conducted in two adjacent rooms. The exper-
imental room (4 × 3.4m) had no windows, was air-conditioned
(22◦C), sound-attenuated, and had a largely non-technical
appearance. Participants sat comfortably in a reclined position.
A 15′′-TFT monitor (Natcomp, Bad Homburg, Germany) and
a response box (XQMS, Frankfurt, Germany) were placed in
front of the participants. Electrodes were connected to a cus-
tomized head box (Neuroscan, Sterling, VA), where EEG and
electrooculogram (EOG) signals were preamplified with a gain
of 30 (input impedance 10M). The adjacent room contained a
32-channel SynAmps 5083 amplifier (Neuroscan, Sterling, USA)
and the technical equipment for experimental control and data
acquisition. A Power Macintosh G4 performed data recording,
data visualization, and data storage using LabView 5.0 soft-
ware (National Instruments, Austin, USA). An IBM-compatible
computer running Presentation 10.3 (Neurobehavioral Systems,
Albany, USA) displayed stimuli and delivered prerecorded
instructions.
PROCEDURE
The experiment was conducted in two separate sessions. In
Session 1 the experimenter conducted a standardized clinical
interview in order to check for lifetime absence of DSM-Axis I
psychiatric disorders. Then participants completed the automated
span task, the CFT and the personality questionnaires. Finally,
they were trained on a attention control task and 2-back working
memory to reduce potential practice effects for pharmaco-session
(Wesnes and Pincock, 2002), in which EEG was recorded.
During Session 2 (starting at 8 a.m.; on average 1.5 days after
session 1; range 1–9 days) the experimenter first conducted a
semi-standardized interview to check protocol compliance (i.e.,
fasting, sleep duration and abstinence from alcohol, cigarettes,
and caffeine for the last 12 h), and then positioned electrodes
and explained emotion self-reports. The experimenter reminded
the participants to sit quietly to help prevent artifacts in the
EEG recordings and participants were told to relax with their
eyes opened for a 10-min rest period with five embedded 1-min
recordings. At the end of the rest period, participants filled in
several self-reports on their current mood (Wacker et al., 2006).
Participants then received either placebo or sulpiride together
with a light breakfast. Thirty minutes after breakfast and sub-
stance intake, the experimental session started. It consisted of
five blocks, with each of these blocks following the same set-up:
first a 4-min rest period at which the EEG data reported here
were recorded, then a 0-back attentional control task, next a 2-
back working memory task to obtain behavioral measures for
dopamine dependent cognitive processes, a 4min post-task wait-
ing phase terminated by a performance feedback, and finally a 30-
min recreation period. A post-experimental semi-standardized
interview concluded the experiment about 5.5 h after medication.
DATA ACQUISITION, RECORDING, AND ANALYSIS
Vertical and horizontal electrooculogram (EOG) was recorded
from four electrodes. EEG was recorded from 29Ag/AgCl sin-
tered ring electrodes (impedances <5 kOhm for EEG, <1 kOhm
for the ground electrode AFZ; <10 kOhm for EOG) positioned
in accordance with the International 10–20 system (Jasper, 1958)
using an elastic electrode cap (Easy Caps, Germany). All sites
were online referenced to Cz. EEG and EOG signals were ampli-
fied with a 32-channel SynAmps 5083 amplifier (EEG: gain 500;
EOG: gain 100; input impedance 10MOhm), digitally filtered
(bandpass 1–50Hz for EEG; lowpass 1 kHz for EOG; 50Hz
Notch filter) and stored (sampling rate: 2 kHz). Then signals
were down-sampled to 250Hz and converted to physical units.
Subsequent pre-processing was carried out using BrainVision
Analyzer 2 (Brain Products, Munich, Germany) and EEGLAB
(Delorme and Makeig, 2004). Low-pass filters were located at
30Hz and high-pass filters at 1Hz. After visual rejection of data
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portions containing non-stereotyped artifacts (e.g., large muscle
artifacts, swallowing, cable movement, etc.), concatenated EEG
data were submitted to extended infomax-independent com-
ponent analysis. Independent components reflecting eye blinks,
lateral eye movements, line noise, and heartbeat pulses were
identified visually and discarded by back-projecting all but these
components to the data space. Corrupted channels flagged as
artifact-contaminated for more than 1/4 of the recording were
estimated using spherical spline interpolation (Perrin et al., 1989).
In 2.13% of the data recordings Fz or Pz needed interpolation.
Overall 2.25 % of the recorded channels were interpolated. Data
portions and recordings with more than two corrupted channels
were discarded. Next, all data epochs of 2.048 s were once again
semi-automatically screened for artifacts.
All artifact free epochs were referenced to average electrodes
and submitted to a Fast Fourier Transform (50% Hamming-
windowed, padded symmetrically with zeros up to 1000 data
points). The resulting estimates of power density (μV2/Hz; reso-
lution 0.25Hz) were clustered into theta (4.00–7.75Hz) and delta
(1.00–3.75Hz) frequency bands both of which were shown to
be sensitive to aE-related baseline/resting differences in poste-
rior vs. anterior power distribution (Chavanon et al., 2011) and
sulpiride (Wacker et al., 2006). Since the pattern of results for
delta frequency data was almost identical to the theta pattern,
we decided to restrict the presentation of results to the latter. As
studies by Knyazev and colleagues (Knyazev, 2009, 2010; Knyazev
et al., 2012) reported aE-related differences in posterior vs. ante-
rior activity for higher frequency bands, we inspected broad alpha
(8–12.75Hz) and beta (13–29.75Hz) frequency bands. All effects
of interest (i.e., Substance, Substance × Time, Substance × Trait
aE, or Substance × Trait aE × Time) were non-significant for
both higher frequency bands, all ps > 0.5.
Power values were normalized by logarithmic transformation
before statistical testing (see e.g., Davidson et al., 2000). The pos-
terior vs. anterior EEG index was computed separately for each
band as ln-transformed power at Pz minus ln-transformed power
at Fz. In order to obtain reliable data recordings, only those
with more than 30 artifact-free epochs (approximately 1min)
were kept (1.25% missing data). On average, EEG-analyses were
based on 71.07 artifact-free epochs (SD = 19.44, range = 31–
121) for post substance periods and 76.19 artifact-free epochs for
the initial pre-drug baseline (SD = 22.18, range = 39–144). The
number of artifact-free epochs was not associated with the Pz-Fz
score, average correlations across data recordings r(79) = −0.05.
To control for individual baseline differences, the main statistical
analysis was performed on reactivity scores computed by sub-
tracting the pre-drug baseline. Prior to this subtraction, we ran
a 2 × 4 ANOVA with Trait aE (2; high, low) and Substance (4;
Placebo, 50, 200, 400mg sulpiride) as group factors. Regarding
posterior vs. anterior activity in theta band, there was neither
significant effect of Substance, F(3, 72) = 0.74, p = 0.53, nor an
interaction effect of Substance × Trait aE, F(3, 72) = 0.56, p =
0.65, for the initial, pre-drug resting period. However, as reported
in detail in Chavanon et al. (2011), there were strong baseline
differences between high and low aE in posterior vs. anterior
theta activity, F(1, 72) = 40.90, p < 0.0001, d = 1.51. High aE
subjects showed more posteriorly located theta activity, whereas
low aE depicted a more frontal pattern (Wacker et al., 2006,
2010). Posterior vs. anterior theta reactivity data was checked for
normality prior to analysis using the Shapiro-Wilk test.
STATISTICAL DATA ANALYSIS
For all dependent variables a 2 × 4× 5 repeatedmeasures ANOVA
with Trait aE (2; high, low) and Substance (4; Placebo, 50, 200,
400mg sulpiride) as group factors and Time (5; 0.5, 1.5, 2.5, 3.5,
4.5 h since substance) as repeated factor was fitted in SAS/STAT
(SAS Institute Inc., 1997) PROC MIXED. The error variance—
covariance matrix was specified as completely general.
Significant ANOVA interactions were followed by a priori-
specified contrasts tested with an α-level of 0.05, two-tailed.
Contrasts for the posterior vs. anterior EEG theta reactivity scores
were specified for three different interactions. These contrasts
depict (a) the Substance × Time interaction regarding sub-
stance effects (placebo vs. sulpiride group) over time, (b) the
Substance × Trait aE interaction focusing on (b1) substance
effects (placebo vs. sulpiride group) within aE groups and (b2)
dose-response relations within aE groups receiving sulpiride (a
priori specified orthogonal contrasts for unequally spaced linear
and quadratic dose-responses across 50, 200, and 400mg), and
finally (c) substance effects (placebo vs. sulpiride group) within
aE groups over time (c1) to identify the first significant substance
effect and (c2) to characterize time courses with orthogonal poly-
nomial trends (linear, quadratic, cubic). Effect sizes (rcontrast) for
those latter repeated measures contrasts on temporal patterns
(i.e., c2) were computed according to Furr and Rosenthal (2003);
otherwise, Cohen’s d was calculated.
RESULTS
PHARMACOLOGICAL SIDE-EFFECTS AND BLINDNESS TO SUBSTANCE
GROUPS
Participants did not report any adverse side effects. The ratings of
nausea and dizziness averaged across experimental phases were
very low (<1 on a 9-point scale with 0 = not at all applica-
ble, 1 = not applicable) in all eight experimental groups. The
percentage of participants, who guessed in a forced choice ques-
tion in the post-experimental interview that they had received
a pharmacologically active substance, did not differ between the
substance groups [placebo: 40%, 400mg sulpiride: 25%, 200mg
sulpiride: 30%, 50mg sulpiride: 40%; Chi2(3) = 1.51, p = 0.68].
When asked to evaluate the confidence in their guess, none of the
participants reported to be 100% sure (M = 66%, SD = 19%).
Thus, it can be concluded that the participants were blind to the
experimental condition as intended.
CHANGES IN POSTERIOR vs. ANTERIOR ACTIVITY
A significant main effect for Trait aE indicated that low compared
to high aE showed a shift toward more posterior vs. anterior EEG
theta [F(1, 72) = 52.85, p < 0.0001,M = 0.076 andM = −0.069,
SEM = 0.014 for low and high aE]. Furthermore, we observed
a significant main effect of Time [F(4, 72) = 9.95, p < 0.0001],
which was best described by a linear trend toward more ante-
rior vs. posterior theta across time [t(72) = −5.65, p < 0.001;
quadratic and cubic trends were non-significant, ps > 0.08]. The
significant interaction effect of Trait aE × Time [F(12, 72) =
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6.73, p < 0.0001] could be traced back to diametrically opposed
quadratic trends [t(72) = −5.58, p < 0.0001]. However, these
effects were further qualified by significant higher order interac-
tion effects (see below).
A Substance main effect [F(3, 72) = 19.23, p < 0.0001]
revealed a linear dose response with 50mg sulpiride inducing
a shift toward stronger posterior theta and 400mg induc-
ing a shift toward a stronger anterior theta [t(72) = 3.89,
p < 0.0025, quadratic ns]. In addition, the expected inter-
action of Substance × Time was observed [F(12, 72) = 6.73,
p < 0.0001]. This interaction effect was due to stronger quadratic
trends over time for sulpiride groups compared to placebo
[t(72) ≥ |1.78|, p ≤ 0.01], with an opposite direction for 50mg
sulpiride compared to 200 [t(72) = 4.06, p = 0.0001] and 400mg,
[t(72) = 4.48, p < 0.0001].
Most importantly, the predicted interactions of Substance ×
Trait aE [F(3, 72) = 18.81, p < 0.0001] and Substance × Trait
aE × Time [F(12, 72) = 3.74, p < 0.001], were also highly signif-
icant. These expected aE based modulations of sulpiride effects
were subsequently probed by a priori contrasts.
A priori contrasts
Substance × Trait aE. The tests of the central a priori con-
trasts are documented in Table 2. The corresponding means (and
SEMs) are shown in Figure 3. High aE participants, who had
received 200 and 400mg sulpiride, exhibited a significant shift
toward more anterior vs. posterior theta distribution compared
to placebo (d = 0.60 for 200mg and d = 1.30 for 400mg) and
the opposite was true for low aE (d = −1.39 for 200mg and
d = −1.01 for 400mg). Compared to placebo the lowest dose
of 50mg sulpiride resulted in changes toward more posterior
theta that were highly significant in low aE (d = −1.67), but
non-significant in high aE (d = −0.35). Dose-response analyses
using orthogonal polynomials for unequally spaced factor lev-
els revealed that linear dose-responses were stronger for high aE
than for low aE [t(72) = 2.89, p = 0.005, d = 0.68]. For quadratic
trends all contrasts were non-significant (ps > 0.25).
Substance× Trait aE×Time. As expected neither placebo group
(high or low aE) showed any significant trends across time (all
t(72) values ≤ |0.95|, ps ≥ 0.35). Figure 4 displays the differen-
tial time courses of reactivity scores observed for high and low aE
Table 2 | Substance effects within and between high and low aE in
posterior vs. anterior theta reactivity: t-values of contrasts (effect
size d).
aE contrasts
Sulpiride effect High aE Low aE High vs. low
Placebo-50 −1.46 (−0.34) −7.08*** (−1.67) 3.98*** (0.94)
Placebo-200 2.54* (0.60) −5.90*** (−1.39) 6.92*** (1.63)
Placebo-400 5.51*** (1.30) −4.28*** (−1.01) 5.97*** (1.41)
Notes: aE, agentic Extraversion; 50, 200, and 400 refer to the groups that
received 50 mg, 200 mg, or 400 mg sulpiride. N = 80. df = 72, *p = 0.05,
***p ≤ 0.001, two-tailed.
within placebo and sulpiride groups. The associated a priori con-
trasts are provided in Table 3. All aE groups that received sulpiride
exhibited significant substance effects. All those effects—except
for high aE 50mg sulpiride—remained significant for at least
three consecutive recording times and, thus, lasted for at least 2 h
(see Table 3).
Under 50mg, high aE significantly differed from their placebo
control group as early as 0.5 h after intake. Notably, for all high
aE groups the first response to sulpiride was a shift toward pos-
terior theta activity, although this shift was not significant for
200 and 400mg sulpiride. Contrasts for high aE participants
further revealed that compared to placebo a first statistically reli-
able response to 200 and 400mg sulpiride occurred after 1.5 h.
While for 200mg the substance-induced shift toward anterior
theta lasted for about 2 h (1.5–3.5 h after intake), it lasted 3 h for
400mg (1.5–4.5 h after intake).
Substance effects occurred earlier in time for low than high
aE: half an hour after substance intake there was a reliable shift
toward posterior theta in all sulpiride groups. While for 400mg
this effect lasted approximately 2 h, substance effects of 200mg
and 50mg were significant for 3 h.
Maximal posteriorization response to 50 and 200mg sulpiride
was delayed compared to 400mg in low aE (2.5 vs. 1.5 h for
50/200 and 400mg, respectively). It should be noted that the lin-
ear dose-response pattern for low aE changed: whereas from 0.5 to
1.5 h after intake 400mg induced stronger effects than 50mg, this
was reversed at 2.5 and 3.5 h. For high aE maximal anterioriza-
tion responses to 400mg and 200mg occurred 2.5 h after intake.
The linear dose-response pattern (400mg > 200mg > 50mg)
remained stable from 2.5 h on.
Characterizing time courses by polynomial trends revealed
that high and low aE depicted opposing quadratic time com-
ponents, and this was true for all sulpiride groups (see t-values
in Table 3). High aE showed an increase in anterior vs.
FIGURE 3 | Disordinal interactions of aE × Substance on posterior vs.
anterior theta reactivity (M and SEM values) contrasting high and low
aE groups which received placebo (PLC) with each of the three
different doses of sulpiride (SLP; 50, 200, or 400mg).
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FIGURE 4 | Interaction of aE, Time and Substance on posterior vs.
anterior theta reactivity (M and SEM values) focusing on time
courses of posterior vs. anterior theta reactivity for high (upper
panel) and low aE groups (lower panel), who received either
placebo (PLC) or one of three different doses of sulpiride (SLP; 50,
200, or 400mg).
posterior theta followed by a decrease, whereas low aE exhib-
ited an increase in posterior vs. anterior theta followed by a
decrease. Within the 50mg sulpiride groups, low aE addition-
ally showed a cubic component that was mainly due to a
sharp rise to posterior theta at 2.5 h and a significant reduc-
tion in posterior theta at 4.5 h (see Figure 4), whereas nonlin-
ear trends for high aE were not significant. After 400mg, both
low and high aE groups depicted an additional linear trend
over time.
WORKING MEMORY PERFORMANCE: 2-BACK TASK
Neither reaction time for correct target responses nor percentage
of correct target responses in the five 2-back tasks showed any
effect related to Substance or aE. In contrast to the percentage
of correct target responses, for which no effects were observed,
reaction times speeded up with each hourly task block [F(4, 72) =
21.25, p ≤ 0.0001].
For reaction time variability we observed an main effect of
Time [F(4, 72) = 4.61, p ≤ 0.003], which was described by a cubic
trend across time [t(72) = 3.28, p < 0.01, all other trends ps >
0.07]. Furthermore, a significant effect of Substance [F(3, 72) =
3.28, p = 0.026] was revealed. Variability was lower under
placebo compared to all doses of sulpiride [t(72) values > 2.23,
ps < 0.03], while there were no significant differences between the
three sulpiride dosages [t(72) values ≤ |0.49|, ps ≥ 0.62; average
variability in ms (SD): placebo 80 (26), 50mg sulpiride 103 (34),
200mg sulpiride 97 (30), 400mg sulpiride 101 (36)].
Controlling for attentional effects in the three performance
measures as measured with the 0-back task (entered as repeated
measures covariate, see Winer, 1971) did not change the pattern
of results.
Grand means for the performance measures are given in
Table 4 for each hour. Note that even in the first task block despite
a comparable percentage of correct target responses, both reac-
tion time and reaction time variability were considerably lower
than in the previous study by Wacker et al. (2006), possibly due
to the practice session on a separate day introduced in the present
work [reaction time (SD) : 444ms (100) vs. 600ms (149), reac-
tion time variability (SD): 98 (31) ms vs. 157ms (53), correct
target responses (SD): 74% (13.3) vs. 72% (17) for present vs.
Wacker et al., 2006, respectively].
SPECIFICITY TO aE
To check whether the effects of sulpiride on posterior
vs. anterior EEG theta activity were modulated by other
(correlated) personality traits (either EPQ-R-neuroticism,
ZKPQ-aggression/hostility, ZKPQ-impulsive sensation seek-
ing, MPQ-negative emotionality), age, weight, general fluid
intelligence or working memory capacity, we calculated a series
of ANCOVAs using the statistical model described above, but
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Table 4 | Grand means (SD) of the performance measures in 2-back
task for each hour since substance intake.
Hours since Target reaction Reaction time Correct target
substance intake time (ms) variability (ms) reactions (%)
1 444 (100) 98 32 74 (13.3)
2 423 (98) 95 35 73 (14.4)
3 409 (92) 94 33 74 (14.8)
4 410 (102) 100 37 72 (15.5)
5 397 (97) 94 31 74 (14.4)
now entering in turn each variable as an additional covariate,
its two-way interaction with Substance, its two-way interaction
with Time and its three-way interaction with Substance and
Time. The results of these supplementary analyses revealed
that the interactions Substance × Trait aE and Substance ×
Trait aE × Time remained significant [Trait aE × Substance:
F(3, 68) ≥ 10.78, p ≤ 0.0001; Trait aE × Substance × Time:
F(12, 68) ≥ 2.31, p ≤ 0.015], indicating that the effects reported
above are indeed specific to aE.
DISCUSSION
The present study focused on paradoxical dopaminergic effects
and confirmed that the effect of sulpiride on posterior vs. ante-
rior theta activity strongly depends on aE. Low aE showed more
frontally distributed theta than high aE, and under 200 and
400mg sulpiride this difference was reversed: high aE showed a
shift toward anterior theta, but low aE, a shift toward posterior
theta. Furthermore, we found marked aE-related response differ-
ences across time. Thus, the present findings support the basic
idea that besides general responses to pharmacological agents and
static models like an inverted U-function, time aspects of phar-
macological effects contain valuable information regarding the
biological basis of Extraversion. While EEG theta activity proved
sensitive to the paradoxical effects of sulpiride on high and low
aE, such effects could not be detected for 2-back working mem-
ory performance. Based on the present findings we will discuss
in detail differential pre- and postsynaptic responses in high and
low E as one possible explanatorymechanism after briefly refresh-
ing the most important features of sulpiride’s pharmacodynamic
profile.
THE PHARMACODYNAMICS OF SULPIRIDE DOSES
Sulpiride shows high affinity within the nanomolar range to D2
and D3 receptors and a weaker affinity within the micromolar
range to D4 receptors (Strange, 2001), and acts predominantly
on the MDS (Mauri et al., 1996). Regarding sulpiride’s biphasic
action and clinical efficacy, the literature suggests that low doses
(50–150mg) affect presynaptic D2/D3-autoreceptors (see review
by Rankin et al., 2009) producing its antidepressant efficacy,
whereas higher doses (>800mg) induce antipsychotic, postsy-
naptic D2 receptor effects (Westerink and Devries, 1989; Serra
et al., 1990; Kuroki et al., 1999). Based on this clinical profile it
is assumed that 50 and 200mg sulpiride used here could induce
both pre- and postsynaptic D2 receptor effects but presynaptic
effects predominate (Mueller et al., 2011). Furthermore, a dose of
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400mg induced stronger striatal occupancy compared to 200mg
(Mehta et al., 2008) and produced a marked decrease in striatal
activation to reward (McCabe et al., 2011). These data suggest
that the inhibition of dopamine transmission (via postsynaptic
effects) predominates the effects of 400mg sulpiride. In a nutshell,
there is a dose-dependent biphasic action that relates to the bal-
ance of pre- to postsynaptic effects (50mg > 200mg presynaptic
vs. 400mg postsynaptic predominance). In addition, pharma-
cokinetic data showed that within the tuberoinfundibular system
the maximal prolactin response to 50 and 200mg are time shifted
(Sugnaux et al., 1983): the response to 50mg sulpiride occurrs1 h
later compared to 200mg. Thus, postsynaptic effects rush in or
dominate later in time for low compared to high doses. Hence one
could expect that in the present study 400mg reach the plasma
levels for pre- and postsynaptic effects in the MDS earlier in time
compared to 200mg and the postsynaptic effects to 50mg -if at
all- will be observed last.
EVALUATION OF INVERTED U-SHAPED MODEL (FIGURE 1)
This model assumes that dopamine and posterior vs. anterior
theta are linked by an inverted U-shaped function and that equal
doses of sulpiride influence dopamine levels in the same, com-
mensurate direction for high and low aE. This implies that all
observed effects are necessarily presynaptic, increasing dopamine
levels. Thus, the model would make the following prediction
for the present data: low aE are typically located on the low
dopamine left side of the inverted U and sulpiride shifts them
up the ascending limb through presynaptic blockade. The same
mechanism pushes high aE up to the top of the curve and beyond
(descending limb). When focusing the time points where sub-
stance effects were most pronounced (0.5–3.5 h; see Figure 5),
this predicition fits the empirical data, although the position of
high aE for the 50mg dose is ambiguous and the size of shifts
differ between high and low aE for the 50mg dose. In addi-
tion, this model focuses on the interaction effect of Trait aE and
Substance, and hence, it cannot explain any of the effects qualified
by time.
EVALUATION OF ALTERNATIVE EXPLANATORY MODELS (FIGURE 2)
Model A assumes that sulpiride produces pre- (50mg) or pre-
and postsynaptic (200, 400mg) responses of similar magnitude
in low and high aE groups that are, however, shifted in time.
Applied to the present datamodel A would suggest that more pos-
terior vs. anterior theta directly tracks dopamine levels (posterior
shift = presynaptic blockade, dopamine increase; anterior shift =
postsynaptic blockade, dopamine decrease). In high aE the presy-
naptic effects are visible under 50mg at 0.5 h. For higher doses
significant presynaptic effects should have appeared before 0.5 h.
Postsynaptic effects for both higher doses started as early as 1.5 h.
Conversely, in low aE only presynaptic effects were evident and
enduring. In neither group postsynaptic net effects were found
within 4.5 h. Although model A can principally account for the
findings, it is necessary to assume that significant portions of the
responses occurred within the first 30min for high aE (missing
parietalization) and after 4.5 h for low aE (missing anterioriza-
tion). These time points were not included in data sampling here.
Given that serum levels of sulpiride have been reported to peak
FIGURE 5 | Projection of the present Substance × aE interaction effect
onto an inverted U-shaped relationship between posterior vs. anterior
theta activity and dopamine level (Figure 1). Postulating such an inverted
U-shaped function implies that sulpiride (SLP) acts presynaptically. In order
to facilitate interpretation we used mean values based on posterior vs.
anterior theta activity across 0.5–3.5 h (i.e., time range of maximal
substance effects). Thus, by increasing dopamine level through presynaptic
sulpiride action, the typical posterior vs. anterior theta activity values of
high and low aE observed under placebo (circles) are shifted to different
locations on this function (squares). For high aE under 50mg sulpiride, the
position on the inverted U-shaped function could either be on the left or the
right arm (indicated by asterisks). The arrows indicate aE-based differences
in the magnitude of presynaptic action (x-axis) to 50mg, which must be
assumed—in either case—in order to accommodate the observed
Substance × aE interaction pattern within the inverted U-shape model.
within a widely varying interval (1–6 h), a direct test of these
assumptions in future studies seems warranted in order not to
dismiss themodel prematurely. However, the observed differences
in response magnitude for high and low aE are not covered by the
model exclusively assuming a aE-related time shift in responses.
Model B holds that in high aE postsynaptic effects should
dominate at least for the two higher doses of sulpiride, whereas for
low aE net presynaptic effects should be observable for all doses,
but particularly for the 50mg dose. In high aE 50mg should gen-
erate at least a small presynaptic response. Once again assuming
that posterior vs. anterior theta directly tracks dopamine levels
the observed pattern closely matches these predictions: low aE
only showed presynaptic effects peaking earlier for the higher
dose than for the lower ones, whereas high aE primarily showed
postsynaptic effects for the two higher doses, with 400mg peak-
ing later than the presynaptic effects observed for low aE. In high
aE we obviously observed an initial presynaptic net effect after
0.5 h for 50mg, but presynaptic effects for 200 and 400mg were
non-significant. An explanation for this pattern in high aE might
be that even under 50mg presynaptic effects are opposed (but
never outweighed) by postsynaptic effects in the time interval
around 1–4.5 h during which peak sulpiride plasma levels most
likely occur. Alternatively, the lack of evidence for more endur-
ing net presynaptic effects in high aE under 50mg may be due to
ceiling effects in our EEG measure (i.e., high aE may have already
demonstrated a maximally posterior distribution of theta activity
under placebo).
It should be noted that aE-related differences in the D2-
like subreceptors DRD2, DRD3, and DRD4 might account for
this pattern. For example, a simple aE-related difference in
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postsynaptic D4 receptors might lead to aE × Substance × Time
interaction because sulpiride’s pharmacological profile expands
across time and additionally stimulates D4 receptors: if low aE
have less DRD4 receptors than high aE they would -in contrast
to high aE- show less DRD4 related postsynaptic effects that typ-
ically rush in when sulpiride reaches micromolar concentrations.
Taken together, model A can accommodate some of the obser-
vations whereas model B can explain the complete pattern of
findings although the precise contribution of D2-like receptors
is not elucidated with the present research.
INTEGRATION OF RECENT RESEARCH
Investigating the posterior vs. anterior EEG theta activity with
polymorphisms related to dopamine D2 receptor functioning,
a recent study showed that SNP19 rs1076560, which is impli-
cated in the regulation of two isoforms of the DRD2 receptor
(Zhang et al., 2007), and -141C Ins/Del rs1799732, which has
been associated with altered expression of the DRD2 in the stria-
tum, were significantly associated with posterior vs. anterior EEG
delta/theta activity (Köhler et al., 2011). Particularly, the SNP19
rs1076560 polymorphism might be relevant to the present data
and their interpretation, because this polymorphism is associ-
ated with relative expression of the DRD2 long isoform (D2L),
which is mainly postsynaptic and the DRD2 short isoform (D2S),
which is mainly presynaptic and serves as an autoreceptor regu-
lating dopamine synthesis and release (Usiello et al., 2000) in the
frontal cortex. Furthermore, D2S receptors are the most abun-
dant autoreceptor subtype in the midbrain (Khan et al., 1998)
and provide potent inhibition of dopamine release. However, the
SNP19 rs1076560 T allele shifts splicing from short to long recep-
tors, decreasing the D2S/D2L ratio relative to the G allele and
therefore the T allele is associated with putatively greater levels
of midbrain dopamine. Köhler et al. (2011) reported that the T
allele compared to the G allele was associated with less posterior
vs. anterior EEG delta/theta activity and carriers had numeri-
cally lower scores in Extraversion. Combining those findings and
the hypothetic principles of tonic and phasic dopaminergic activ-
ity (Grace, 1991) would lead to the following prediction: low aE
mightmore frequently be carriers of the T-allele and consequently
have higher tonic midbrain dopamine levels. High dopamine
levels result in a lower (phasic) responsivity of postsynaptic recep-
tors, leading sulpiride’s presynaptic effects to prevail. For high
aE the lower dopamine level results in higher responsivity of
postsynaptic receptors, leading to sulpiride’s postsynaptic effects
to prevail. This is exactly what we found in the present study.
Combining the present pharmacological design with the genetic
approach used in Köhler et al. (2011) could provide a direct test
of this model.
Regarding the functional significance of the posterior vs. ante-
rior theta measure, there are some aspects we would like to
point out. As anterior theta is generated in ACC (Ishii et al.,
1999), we recently probed the ACC as a potential source of pos-
terior vs. anterior theta and found that especially theta in the
rostral portion (rACC) was strongly associated with low values
in our EEG measure (Chavanon et al., 2011). In line with the
present results, ACC is known to respond to dopaminergic chal-
lenges (Vollm et al., 2004). Interestingly, high levels of inhibitory
rACC delta/theta activity (i.e., presumably low ACC activity) have
been associated with both blunted nucleus accumbens reward
responses and anhedonia, i.e., reward-insensitive behavior and
blunted positive emotionality or, arguably, extremely low aE
(Wacker et al., 2009). Furthermore, ACC activity predicts the
psychopharmacological treatment response in depressive patients
(Korb et al., 2009). Thus, low aE individuals may have demon-
strated a sulpiride-induced “antidepressive” reaction in rACC
mirrored by posterior vs. anterior theta. Pizzagalli (2011) recently
argued that the rACC plays a key role in treatment outcomes
due to its prominent position in the default network. He related
the antidepressive rACC response to adaptive self-referential pro-
cessing which parallels our suggestion that posterior vs. anterior
theta (and low inhibitory rACC theta) is positively associated with
optimistic future-oriented mentation about one’s self and per-
sonally significant issues (Chavanon et al., 2011). However, data
by Knyazev and colleagues (Knyazev, 2012, 2013; Knyazev et al.,
2012) and unpublished data from our group supported the idea
that aE is associated with higher theta activity in the default mode
network.
Regarding the posterior component of the posterior vs. ante-
rior theta index, Chavanon et al. (2011) reported that inferior
parietal and insular cortex were negatively associated with aE.
Those results converge with a recent study showing that the
insula is inversely related to the willingness to work for reward
(Treadway et al., 2012), which is a major facet of aE (i.e., per-
sistent reward striving). Because the insula receives dopaminergic
innervation (Gaspar et al., 1989) and expresses D1-like and as well
as to a lesser extent D2-like receptors (Hurd et al., 2001), it can
be speculated that—in addition to the rACC—the insula might
have contributed to the results presented here. Other structures
which might have contributed could be the inferior parietal cor-
tex, precuneus and posterior cingulate which were a) functionally
connected to the striatum under resting conditions (Di Martino
et al., 2008) and b) recently linked to extraversion (Knyazev,
2013). However, it should be kept in mind that based on its neu-
roanatomy, the dopaminergic system exerts its influence more
strongly on frontal brain structures than on posterior brain struc-
tures (Cools and D’Esposito, 2011). Thus, compared to Chavanon
et al. (2011), the present data presumably rely more heavily on the
anterior component of the theta index due to the pharmacological
manipulation of the MDS.
LIMITATIONS
The following caveats should be noted: (1) The present study
was conducted with male participants and thus leaves general-
izability to women open. (2) The assessment of sulpiride effects
was limited to posterior vs. anterior theta activity and 2-back
workingmemory performance. In contrast toWacker et al. (2006)
who reported diametrically opposite effects onmultiple levels, the
present paradoxical effects were restricted to the EEG measure.
Unfortunately, we cannot explain the lack of effects on work-
ing memory performance. Because other biological indicators
such as plasma dopamine levels were not assessed, a valida-
tion of the EEG measure with other dopamine biomarkers or
a dopmamine-related cognitive phenotype is missing here. (3)
Although sulpiride is a highly selective dopamine D2 receptor
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antagonist, we cannot rule out that the effects observed are due
to interactions with other neurotransmitter systems rather than
purely dopaminergic. (4) Furthermore, we cannot rule out that
there were substance effects before our initial measurement at
30min and after the final measurement at 4.5 h. Thus, a definitive
conclusion concerning the time-course model requires a study
with an evenmore extended recording interval. (5) The exact con-
CONCLUSIONS
Using resting posterior vs. anterior theta activity, we demon-
strated that sulpiride’s effects play out differently for individuals
high and low in aE. Whereas the present findings cannot fully
rule out that these differences are exclusively due to shifts in
the time course of the drug responses, a more parsimonious
model holds that low aE individuals are more sensitive to presy-
naptic, and high aE to postsynaptic sulpiride effects. These
data not only add to the still limited evidence for a dopamin-
ergic basis of aE, but also help to generate new hypotheses
on the neurobiological mechanisms underlying the frequently
observed paradoxical effects of dopaminergic drugs: pre- and
postsynaptic reactivity depends on personality-correlated base-
line dopamine levels. This factor contributes to the variabil-
ity in the EEG-effects and possibly to the clinical efficacy of
dopaminergic drugs. Future research may probe these sugges-
tions and investigate the molecular basis of individual differences
in pre- vs. postsynaptic dopamine D2 subreceptor densities and
sensitivities.
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